Company Overview
About BillionToOne
BillionToOne is a leading molecular diagnostics company that has commercialized a proprietary technology platform—Quantitative Counting Templates (QCTs)—enabling detection and quantification of disease-related DNA at single base-pair resolution. This breakthrough in cell-free DNA (cfDNA) analysis underpins its two primary product lines: UNITY Screen for comprehensive prenatal genetic screening (covering carrier status, chromosomal conditions, and fetal risk) and Northstar Select for oncology therapy guidance and liquid biopsy.
Business Model & Competitive Advantage
The company completed a landmark IPO in November 2025, raising approximately $273M through the sale of 4.55 million shares at $60 each, with Class A common stock trading on the Nasdaq Global Select Market under the ticker BLLN. Prior to the IPO, BillionToOne had raised $130M in an oversubscribed Series D at a $1B+ valuation in June 2024. The company processed over 508,000 tests in the year ending June 2025, surpassing 1 million cumulative tests since launch.
Competitive Landscape 2025–2026
For FY2025, BillionToOne guided to $293–299M in revenue with positive GAAP operating income—a rare profitability milestone for a clinical-stage diagnostics company. The company has integrated its prenatal and oncology tests with Epic EHR, extending clinical reach into large health systems. BillionToOne's single-molecule precision positions it as a platform diagnostic company, with QCT technology applicable across an expanding range of genetically driven diseases.
Key Differentiators
Market Leader
BillionToOne is recognized as a market leader in the Life Sciences & BioTech sector, demonstrating strong industry presence and customer trust.
Frequently Asked Questions
Similar Brands
BioNTech
BioNTech SE was founded in 2008 in Mainz, Germany by Ugur Sahin, Ozlem Tureci, and Christoph Huber with a mission to harness the immune system for individualized cancer treatment. The company pioneere
Illumina
Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applicat
Neuralink
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with pa
Genentech
Genentech was founded in 1976 in South San Francisco by Herbert Boyer and Robert Swanson, becoming the first company to produce human insulin using recombinant DNA technology and essentially launching
Regeneron
Regeneron Pharmaceuticals was founded in 1988 in Tarrytown, New York by Leonard Schleifer and George Yancopoulos. The company built its reputation on the Velocimmune platform—a proprietary humanized m
Pliant Therapeutics
Pliant Therapeutics develops small molecule integrin inhibitors targeting the pathological tissue scarring (fibrosis) that drives diseases including idiopathic pulmonary fibrosis (IPF), primary sclero
Compare BillionToOne with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from BillionToOne? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim BillionToOne Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention BillionToOne vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →